Alpha Teknova (TKNO) Presents At 42nd Annual Cowen Health Care Conference

Company Overview - Teknova is a leading provider of research and clinical-grade reagents, supporting drug discovery, development, and production[6] - The company has a strong competitive position with expertise in custom reagent manufacturing and short turnaround times[6] - Teknova produces bioprocessing tools for cell & gene therapy, creating a breakthrough growth opportunity[6] - The company has over 3,000 active customers[7,27] Financial Performance - Trailing Twelve Months (TTM) core revenue was $33.4 million[7] - TTM core growth was 37%[7] - Clinical (GMP) TTM growth was 71%[7] - Total revenue increased by 41% year-over-year[53] - Q3 2021 total revenue was up 5% year-over-year, or 26% excluding Sample Transport[71] Cell & Gene Therapy Market - The global cell & gene therapy market is expected to grow from $2.3 billion in 2020 to $45.4 billion in 2026, a 64% CAGR[29] - Teknova is a supplier to more than 65 leading cell & gene therapy organizations[40] - 62% of Teknova's accounts are in the research & discovery phase[42] Investments and Future Targets - The company is investing to support rapid growth to revenue of $100 million+[45] - Teknova is expanding production capacity five-fold[49] - The target model includes sustainable 25%+ revenue growth, 65%+ gross margin, and 25-30% adjusted EBITDA margin[66]